Soligenix applies for CEPI funding to develop Bundibugyo Ebola vaccine

Go back to Soligenix applies for CEPI funding to develop Bundibugyo Ebola vaccine

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

June 8, 2026 7:30 AM EDT

Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development

PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)... More